Veterinary pharmaceutical compositions for direct systemic introduction
Veterinary pharmaceutical compositions for direct systemic introduction, also known as DSI pharmaceutical compositions. One veterinary pharmaceutical composition for direct systemic introduction includes about 10-17 dry mass % bovine gelatin; about 10-17 dry mass % mannitol; about 0-1 dry mass % of a surfactant; and about 65-80 dry mass % of the active pharmaceutical ingredient which is a proton pump inhibitor. A method of manufacturing a veterinary pharmaceutical composition for direct systemic introduction includes combining one or more pharmacologically inactive compounds to form a first solution; using one or more surfactants to form a second solution; adding an active pharmaceutical ingredient to the second solution to form a first mixture; adding the first solution to the first mixture to form a pre-formulation; freezing the pre-formulation; and lyophilizing the pre-formulation.
1. A veterinary pharmaceutical composition for direct systemic introduction, comprising:
about 10-17 dry mass % bovine gelatin;
about 10-17 dry mass % mannitol;
about 0-1 dry mass % of a surfactant; and
about 65-80 dry mass % of the active pharmaceutical ingredient which is a proton pump inhibitor;
wherein the veterinary pharmaceutical composition further comprises an H2 receptor antagonist.
2. The veterinary pharmaceutical composition according to claim 1 , comprising:
about 10-13 dry mass % of the bovine gelatin;
about 12-15 dry mass % of the mannitol; and
about 0.1-0.3 dry mass % of the surfactant.
3. The veterinary pharmaceutical composition according to claim 1 , wherein the proton pump inhibitor is omeprazole or esomeprazole.
4. The veterinary pharmaceutical composition according to claim 3 , wherein the proton pump inhibitor comprises micronized omeprazole having an average particle diameter of about 1 to about 10 microns.
5. The veterinary pharmaceutical composition according to claim 1 , having a disintegration time of 7 seconds or less in deionized water maintained at 37.0° C.±0.5° C.
6. The veterinary pharmaceutical composition according to claim 1 , having a disintegration time of 4 seconds or less in deionized water maintained at 37.0° C.±0.5° C.
7. The veterinary pharmaceutical composition according to claim 1 , wherein the veterinary pharmaceutical composition further comprises about 0-0.5 dry mass % of a flavorant or sweetener.
8. The veterinary pharmaceutical composition according to claim 1 , wherein the veterinary pharmaceutical composition is characterized by a pH adjusted to about 8.3±0.2.
9. The veterinary pharmaceutical composition according to claim 1 , wherein the H2 receptor antagonist comprises at least one compound selected from the group consisting of famotidine, cimetidine, ranitidine, and nizatidine.
10. A method of manufacturing a veterinary pharmaceutical composition for direct systemic introduction, the method comprising:
combining one or more pharmacologically inactive compounds to form a first solution;
using one or more surfactants to form a second solution;
adding an active pharmaceutical ingredient to the second solution to form a first mixture;
adding the first solution to the first mixture to form a pre-formulation;
freezing the pre-formulation; and
lyophilizing the pre-formulation;
wherein the veterinary pharmaceutical composition comprises:
about 10-17 dry mass % bovine gelatin;
about 10-17 dry mass % mannitol;
about 0-1 dry mass % of a surfactant; and
about 65-80 dry mass % of the active pharmaceutical ingredient which is a proton pump inhibitor.
11. The method according to claim 10 , wherein the method further comprises reducing the pressure surrounding the pre-formulation prior to lyophilizing the pre-formulation.
12. The method according to claim 10 , wherein the veterinary pharmaceutical composition further comprises about 0-0.5 dry mass % of a flavorant or sweetener.
13. The method according to claim 10 , wherein the first solution comprises at least the bovine gelatin and the mannitol.
14. The method according to claim 10 , wherein the second solution comprises at least the surfactant.
15. The method according to claim 10 , wherein the method further comprises adjusting the pH of the pre-formulation using Sodium Hydroxide.
16. The method according to claim 15 , wherein the pH is adjusted to about 8.3±0.2.
17. The method according to claim 10 , wherein the active pharmaceutical ingredient comprises omeprazole or esomeprazole.
18. The method according to claim 10 , wherein the active pharmaceutical ingredient comprises micronized omeprazole having an average particle diameter of about 1 to about 10 microns.
19. The method according to claim 10 , wherein the veterinary pharmaceutical composition further comprises an H2 receptor antagonist.